{"id":2892,"date":"2016-12-07T01:38:09","date_gmt":"2016-12-07T01:38:09","guid":{"rendered":"http:\/\/www.medicalmarijuanainc.com\/?p=18626"},"modified":"2016-12-07T01:38:09","modified_gmt":"2016-12-07T01:38:09","slug":"axim-biotechnologies-moves-secure-rights-proprietary-method-extracting-high-purity-thc","status":"publish","type":"post","link":"https:\/\/medicalmarijuanainc.com\/2016\/12\/07\/axim-biotechnologies-moves-secure-rights-proprietary-method-extracting-high-purity-thc\/","title":{"rendered":"AXIM\u00ae Biotechnologies Moves to Secure Rights to Proprietary Method for Extracting High-Purity THC"},"content":{"rendered":"
Medical Marijuana, Inc. investment company <\/span>AXIM\u00ae Biotechnologies<\/span><\/a> has had a booming past couple of months, seeing its stock soar nearly 2000 percent year to date. Much of this growth has occurred because of the company\u2019s tireless innovation in their mission to create cannabinoid-based treatments for difficult to treat conditions. <\/span><\/p>\n Most recently, AXIM\u00ae Biotechnologies has filed an <\/span>intellectual property (IP) application<\/span><\/a> with the World Intellectual Property Organization (WIPO) covering its proprietary method to extract and refine high-purity THC from cannabis plant material. <\/span><\/p>\n The company\u2019s recently-filed IP application would provide protection to the invention of a method of extracting THCa from cannabis flower using a non-polar solvent where the yield is approximately 50 \u2013 70 percent with regards to THCa content in the starting material. <\/span><\/p>\n Because the process allows the company to recover more THCa, a precursor of THC, \u00a0AXIM\u00ae\u2019s proprietary extraction method helps the company to achieve THC extracts with a greater purity than conventional extractions being used in the market today. The extracted THCa is decarboxylated in a final step in a water\/ethanol solution that renders THC at a purity greater than <\/span>98 percent<\/span><\/a>. Standardizing this stage in its process is critical to the company\u2019s development of cannabinoid-based pharmaceuticals, and the IP application protects its innovation, placing AXIM\u00ae in a competitive position to dominate the market.<\/span><\/p>\n This news comes on the heels of a number of other achievements by AXIM\u00ae Biotechnologies in the past few months, causing the company\u2019s value to skyrocket. <\/span><\/p>\n AXIM\u00ae recently announced an <\/span>extension was awarded<\/span><\/a> to the company\u2019s patent on delayed-release cannabidiol gum to now include all cannabinoids. This gives AXIM\u00ae unique control over the use of delayed-release chewing gum as a delivery method for cannabinoid-based treatments for a range of medical indications. <\/span><\/p>\n Earlier in the year, AXIM\u00ae announced that it had <\/span>secured the necessary funding<\/span><\/a> to move forward on several cannabinoid-based clinical trials, including trials on its MedChew\u00ae RX, CanChew\u00ae Plus, and AX-1602 topically applied cannabinoid ointment. The company also published a <\/span>development pipeline chart<\/span><\/a> to reveal their new drug schedule for the coming months and years.<\/span><\/p>\n Keep up with the achievements of AXIM\u00ae Biotechnologies and the other Medical Marijuana, Inc. investment companies by following <\/span>our news feed<\/span><\/a>. <\/span> \t<\/p>\n","protected":false},"excerpt":{"rendered":" Medical Marijuana, Inc. investment company AXIM\u00ae Biotechnologies has had a booming past couple of months, seeing its stock soar nearly 2000 percent year to date. Much of this growth has occurred because of the company\u2019s tireless innovation in their mission to create cannabinoid-based treatments for difficult to treat conditions. Most recently, AXIM\u00ae Biotechnologies has filed […]<\/p>\n","protected":false},"author":1,"featured_media":208,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[160,3],"tags":[183,49],"class_list":["post-2892","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-axim-biotechnologies","category-company-news","tag-axim-biotechnologies","tag-medical-marijuana-inc"],"yoast_head":"\n